A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

How it works Patient-specific parameters

A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

How it works Patient-specific parameters

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

Patient-specific parameters

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

Patient-specific parameters

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FRI benefits

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FRI benefits

“FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.“

Mark Milton – Edwards Global Dir. Respiratory, TEVA

“FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.“

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

“FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.“

Mark Milton – Edwards Global Dir. Respiratory, TEVA

“FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.“

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

Bronchial thermoplasty increases airway volume measured by Functional Respiratory Imaging (FRI)

In a  recently published study (ref)10 patients with unstable, severe asthma were treated with bronchial thermoplasty of the left lung,
Read More

FLUIDDA attends the International Conference of Medical imaging with Deep Learning

During July 8-10 the International Conference of Medical imaging with Deep Learning takes place in London. The FLUIDDA team, specialised
Read More

FLUIDDA will be present at the Annual Drug Discovery & Development Symposium on Pulmonary Vascular Disease

This year's symposium will take place in Paris on July 1-2. Each year the meeting brings leading scientists in the
Read More

Jan de Backer, CEO and founder of Fluidda, speaks about the partnership with Materialise at the ATS conference.

De Backer states: “We are very excited and proud to enter into this new phase of partnership with Materialise. We
Read More

All content © FLUIDDA 2019